These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29113548)

  • 21. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
    BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
    Ko K; Yang DY; Lee WK; Kim SW; Moon du G; Moon KH; Park NC; Park JK; Son HC; Lee SW; Hyun JS; Park K
    Korean J Urol; 2014 Sep; 55(9):608-14. PubMed ID: 25237463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
    Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
    Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving picture of lower urinary tract symptom management.
    Tubaro A; De Nunzio C; Puccini F; Presicce F
    Eur Urol; 2015 Feb; 67(2):271-2. PubMed ID: 25457016
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
    Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
    World J Urol; 2017 May; 35(5):827-838. PubMed ID: 27514371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.
    Rees J; Foley S; Huang M; Rosa Arias J; Skoumal R; Walters C; Yavuz Y; De Wachter S
    Neurourol Urodyn; 2019 Mar; 38(3):981-989. PubMed ID: 30801782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Aging Male; 2015 Mar; 18(1):44-8. PubMed ID: 25136746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study.
    Dellis AE; Papatsoris AG; Keeley FX; Bamias A; Deliveliotis C; Skolarikos AA
    J Endourol; 2017 Jan; 31(1):100-109. PubMed ID: 27809592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence.
    Kosilov K; Kuzina I; Loparev S; Gainullina Y; Kosilova L; Prokofyeva A
    Int Neurourol J; 2018 Mar; 22(1):41-50. PubMed ID: 29609422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial.
    Park J; Yoo C; Han DH; Shin DW
    World J Urol; 2015 Nov; 33(11):1833-40. PubMed ID: 25809877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
    Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
    Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.
    Henningsohn L; Kilany S; Svensson M; Jacobsen JL
    Aging Male; 2017 Dec; 20(4):266-276. PubMed ID: 28787230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
    Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
    J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem.
    Angulo JC
    Curr Med Res Opin; 2015 Nov; 31(11):1963-5. PubMed ID: 26368336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α
    Urakami S; Ogawa K; Oka S; Hagiwara K; Nagamoto S; Anjiki H; Hayashida M; Yano A; Sakaguchi K; Kurosawa K; Okaneya T
    Low Urin Tract Symptoms; 2019 May; 11(3):109-114. PubMed ID: 30251330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.